EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Albuminuria in Cardiovascular, Kidney, and Metabolic Disorders: A State-of-the-Art Review

Sophie E Claudel iD, Ashish Verma iD

Circulation · 11.03.2025 · 151 (10) · 716-732

DOI: 10.1161/circulationaha.124.071079 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Circulation, erschienen am 11.03.2025. Verfasst von Sophie E Claudel und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Boston Medical Center, MA (S.E.C., A.V.). Hauptthemen laut MEDLINE: Albuminuria, Cardiovascular Diseases, Metabolic Diseases, Kidney Diseases. Die Arbeit wurde bisher 141-mal zitiert (Crossref) und nennt 162 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Albuminuria—increased urine albumin excretion—is associated with cardiovascular mortality among patients with diabetes, hypertension, chronic kidney disease, or heart failure, as well as among adults with few cardiovascular risk factors. Many authors have hypothesized that albuminuria reflects widespread endothelial dysfunction, but additional work is needed to uncover whether albuminuria is directly pathologic or causative of cardiovascular disease. Urinary albumin-to-creatinine ratio is an attractive, unifying biomarker of cardiovascular, kidney, and metabolic conditions that may be useful for identifying and monitoring disease trajectory. However, albuminuria may develop through unique mechanisms across these distinct clinical phenotypes. This state-of-the-art review discusses the role of albuminuria in cardiovascular, kidney, and metabolic conditions; identifies potential pathways linking albuminuria to adverse outcomes; and provides practical approaches to screening and managing albuminuria for clinical cardiologists. Future research is needed to determine how broadly and how frequently to screen patients for albuminuria, whether it is cost-effective to treat low-grade albuminuria (10–30 mg/g), and how to equitably offer newer antiproteinuric therapies across the spectrum of cardiovascular-kidney-metabolic diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlbuminuriaCardiovascular DiseasesMetabolic DiseasesKidney DiseasesHumansBiomarkersRisk FactorsKidney

Stichwörter der Autor:innen

albuminuriacardiovascular diseasesmetabolic syndromerenal insufficiency, chronic

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Medicine, Boston Medical Center, MA (S.E.C., A.V.).
  • Department of Medicine, Section of Nephrology, Boston University Chobanian & Avedisian School of Medicine, MA (S.E.C., A.V.).

ORCID-Profile: Sophie E Claudel, Ashish Verma

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Claudel, S. E., & Verma, A. (2025). Albuminuria in Cardiovascular, Kidney, and Metabolic Disorders: A State-of-the-Art Review. Circulation, 151(10), 716-732. https://doi.org/10.1161/circulationaha.124.071079

Vancouver

Claudel SE, Verma A. Albuminuria in Cardiovascular, Kidney, and Metabolic Disorders: A State-of-the-Art Review. Circulation. 2025;151(10):716-732. doi:10.1161/circulationaha.124.071079

BibTeX
@article{Claudel2025,
  author = {Claudel, Sophie E and Verma, Ashish},
  title = {Albuminuria in Cardiovascular, Kidney, and Metabolic Disorders: A State-of-the-Art Review},
  journal = {Circulation},
  year = {2025},
  volume = {151},
  number = {10},
  pages = {716--732},
  doi = {10.1161/circulationaha.124.071079}
}
Kostenlos starten →